Immediate Impact

48 standout
Sub-graph 1 of 15

Citing Papers

Gastric cancer treatment: recent progress and future perspectives
2023 Standout
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
2022 Standout
2 intermediate papers

Works of Åsa Dahle-Smith being referenced

Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma
2015
Patient-reported outcomes from a phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib (COG).
2013

Author Peers

Author Last Decade Papers Cites
Åsa Dahle-Smith 29 38 26 7 46
Fabiana Sousa 18 31 24 8 52
M Varcada 46 20 21 6 59
Isabel Cuenca 30 31 17 5 45
Carlos Adame 12 39 28 7 55
Erica Mazzotta 40 13 12 7 58
Fabio Pulighe 36 14 30 9 62
Jean-Christophe Saurin 27 32 17 8 51
Isabel Alemany 16 16 11 6 46
Stephen McCain 26 18 15 11 55
Anne Miek Koenen 10 24 16 6 44

All Works

Loading papers...

Rankless by CCL
2026